| 52 Week Rng | - |
| Market Cap | - |
| Avg Volume | - |
| 1M Volatility | - |
| Short Ratio | - |
| P/E Ratio (TTM) | - |
| P/E Ratio (Fwd) | - |
| P/B Ratio | - |
| Div & Yield | - |
IRAM2022Team1 • IRAM 2022 • Mar 2022
From financials, abbvie not only has revenues but also profits, which is a demonstration of value generation and therefore a good fit for long-only investment. Abbvie's EPS has been growing steadily over the years and its most recent EPS growth rate reaches 21% over the three years. Abbvie's EBIT margins are steadily maintained over the last year as well. From activities, Abbvie very recently buys Belgian drug company Syndesi Therapeutics for about $130 million to give it ownership of the firm in neuroscience field like cognitive decline and depression. Building upon company's expertise in immunology, the firm will now have more development in neuroscience field as well, which represents potentials in growth from such diversification.
WSmursus • Aalto Investment management game (Fall 2021) • Dec 2021
Monthly Rebalance / Buying and selling Top 50 Market cap S&P 500 stocks to achieve target weights of max 2% per stock
traders123 • Aalto Investment management game (Fall 2021) • Dec 2021
Closing position
According to our seasonality strategy we sell our long positions and close our short positions for November, now that we enter into December. We have a long position in this stock and thus, we sell it.
jjaldin • Stockfuse Continuum (US) • Nov 2021
Automatic trade executed by Stockfuse to ensure margin compliance.